Background: Pediatric nonrhabdomyosarcoma soft tissue sarcomas (NRSTS) may rarely occur in visceral tissues, and little is known about their clinical history. The present study retrospectively analyzed a group of patients prospectively registered in Italian pediatric protocols conducted between 1979 and 2004.

Methods: Inclusion criteria for the study were as follows: a pathological diagnosis of "adult-type NRSTS," arising at visceral sites (lung-pleurae, liver, kidney, and mesentery-bowel); age under 18 years; no previous treatment except for primary surgery; available clinical data; and written consent.

Results: Thirty cases with visceral NRSTS were collected and analyzed. Sites of origin were as follows: mesentery-bowel in 12 cases, lung-pleurae in 11, liver in 5, and kidney in 2. According to the Intergroup Rhabdomyosarcoma Study (IRS) surgical grouping system, patients were classified as follows: nine IRS group I, three group II, 12 group III, and six group IV. Patients were treated with a multimodal approach including surgery, radiotherapy, and/or chemotherapy, according to their characteristics. For the series as a whole, the 5-year event-free and overall survival rates were 33.3% and 40.0%, respectively. The IRS group (reflecting the feasibility of initial complete resection) emerged as the main prognostic factor. Survival rates also correlated with tumor size and local invasiveness, histological subtype, and tumor sites (the worst outcome was seen for tumors arising in the lung and pleurae).

Conclusions: This study confirmed that visceral NRSTS are aggressive tumors carrying a worse prognosis than pediatric NRSTS arising in soft tissues of the extremities. Local treatment remains the main challenge for these tumors.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.26490DOI Listing

Publication Analysis

Top Keywords

pediatric nonrhabdomyosarcoma
8
nonrhabdomyosarcoma soft
8
soft tissue
8
tissue sarcomas
8
arising visceral
8
visceral sites
8
group patients
8
lung-pleurae liver
8
liver kidney
8
visceral nrsts
8

Similar Publications

Article Synopsis
  • The study investigated the expression of VEGFRs, PDGFRs, and c-Kit in pediatric patients with high-grade non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) to understand their impact on growth, invasion, and treatment outcomes.
  • Out of 113 pediatric patients analyzed, about one-third showed high expression of PDGFRα, while other markers had lower expression rates; high PDGFRα and VEGFR2 were notably associated with poorer survival rates.
  • The results suggest that these tyrosine kinase receptors are upregulated in NRSTS, indicating a potential for targeted therapies to improve outcomes in affected patients.
View Article and Find Full Text PDF

Objective: The current treatment of pediatric non-rhabdomyosarcoma soft tissue sarcomas (NRSTS) is a multimodal risk-based approach. Today, smaller fields and lower doses of radiotherapy (RT) have become standard. In this study, it was aimed to evaluate the treatment outcomes and toxicity profile in children with NRSTS that received RT as a part of multimodal therapy.

View Article and Find Full Text PDF

Contemporary surgical management of pediatric non-rhabdomyosarcoma soft tissue sarcoma.

Pediatr Blood Cancer

November 2024

Division of Pediatric General and Thoracic Surgery, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA.

Non-rhabdomyosarcoma soft tissue sarcoma (STS) comprises most STS in pediatric patients. It is a diverse set of over 30 histologic subtypes. Treatment is based on risk group determined by tumor size, grade, and the presence of metastases.

View Article and Find Full Text PDF
Article Synopsis
  • The study focuses on outcomes for pediatric low-grade non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), analyzing data from patients under 30 years old enrolled in a specific clinical trial.
  • Low-risk patients were treated with surgery alone, leading to high survival rates (90% event-free and 100% overall), while intermediate- and high-risk groups had significantly lower survival rates (55% event-free and 25% overall) despite aggressive treatment.
  • Findings suggest that most low-risk patients can be effectively managed with surgery only, and the current grading system may over-treat some patients who do not need additional therapies beyond surgery.
View Article and Find Full Text PDF

Proton Therapy in Non-Rhabdomyosarcoma Soft Tissue Sarcomas of Children and Adolescents.

Cancers (Basel)

April 2024

Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale Tumori, 20133 Milano, Italy.

This paper provides insights into the use of Proton Beam Therapy (PBT) in pediatric patients with non-rhabdomyosarcoma soft tissue sarcomas (NRSTS). NRSTS are a heterogeneous group of rare and aggressive mesenchymal extraskeletal tumors, presenting complex and challenging clinical management scenarios. The overall survival rate for patients with NRSTS is around 70%, but the outcome is strictly related to the presence of various variables, such as the histological subtype, grade of malignancy and tumor stage at diagnosis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!